Milestones

The Centres of Excellence for Commercialization and Research framework (CECR) enabled PC-TRiADD to build a solid foundation and gain momentum toward our objectives.  Since our inception in 2008, we have:

  • Attracted over $18 million in research contracts and $92.1 million in peer-reviewed funding, through the structuring of our core platforms to form an integrated contract research enterprise
  • Expanded High Quality Personnel and management to include an experienced executive team
  • Expanded our portfolio of IP protected targets and drug candidates that tackle treatment resistance that are translating into commercialization activities, with 277 patents filed/issued
  • Established 9 licensing agreements of IP with industry (8 drug, 1 biomarker)
  • Attracted increased global funding allowing us to initiate 125 new clinical trials, the majority of which are either peer reviewed, grant funded or are sponsored by pharmaceutical companies

News

Dec 07 2017

Dr. Wyatt receives a CIHR Early Career Investigator Award

Dr. Alex Wyatt has been awarded a CIHR Early Career Investigator Award for $345,000 over 3 years.  His project aims to develop a procedure that will enable the identification of metastatic bladder cancer patients most likely to respond to specific therapies.

Read more